Anemia Drugs Up Cancer Death Risk
Study Shows More Deaths, Blood Clots in Cancer Patients Taking Procrit, Epogen, Aranesp
Whither Procrit, Epogen, Aranesp? continued...
"I think the fear among oncologists is that the ESAs may just be removed
from all cancer indications, and I don't know that is the best decision,"
he says. "You begin with patients with severe cancers who have severe
treatment-related side effects. You have to balance the benefits of ESAs
against the risks of what could happen to a patient's tumors if you use the
Bennett, Lai, and colleagues report their findings in the Feb. 27 issue of
The Journal of the American Medical Association.